Skip to main content
Cell & Gene

Manufacturing CGTs: Should I Use A CDMO?

September 30, 2022
Authors
Deeona R. GaskinRaj D. Pai

Sidley lawyers Deeona Gaskin and Raj Pai recently published an article in Cell & Gene entitled “Manufacturing CGTs: Should I Use A CDMO?” The article explains various manufacturing challenges faced by sponsors of cell and gene therapies, and considerations for companies looking to outsource manufacturing of their cell and gene therapy products to contract manufacturing organizations (CMOs) or contract development and manufacturing organizations (CDMOs).

Click here to view the article.

Contacts

Gaskin, Deeona R.
パートナー
Pai, Raj D.
パートナー

Related Blogs

Capabilities

Suggested News & Insights

Sidley Lawyer Michael Borden To Speak on “The Biosecure Act: What Chinese Biotech and Life Sciences Companies Need To Know” WebinarThursday, December 18, 2025
Events
U.S. Drug Pricing Year in Review: Reflections on 2025 and Getting Ready for 2026December 12, 2025
GoodLifeSci
What the U.S.–UK Drug Pricing Agreement Reveals About How MFN Drug Policy Could Impact the UK and EUDecember 10, 2025
GoodLifeSci
U.S. FDA's Adoption of ICH E6(R3) Good Clinical Practice: Key Takeaways for Sponsors and InvestigatorsDecember 4, 2025
Global Life Sciences Update
Navigating an Uncertain Market Amidst Cautious Optimism: Steps Biotech Companies Can Take to Hedge Against Financial FluctuationsNovember 18, 2025
GoodLifeSci
SEC Remains Focused on Public Disclosures Made By Life Sciences CompaniesOctober 29, 2025
GoodLifeSci